<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05043558</url>
  </required_header>
  <id_info>
    <org_study_id>LHD Beraprost sodium</org_study_id>
    <nct_id>NCT05043558</nct_id>
  </id_info>
  <brief_title>The Protective Effect of Prostaglandin on Coronary Microcirculation and Ventricular Remodeling After Reperfusion Therapy in Acute ST-segment Elevation Myocardial Infarction</brief_title>
  <official_title>The Protective Effect of Prostaglandin on Coronary Microcirculation and Ventricular Remodeling After Reperfusion Therapy in Acute ST-segment Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the protective effect of prostaglandin sodium on coronary microcirculation&#xD;
      function and ventricular remodeling after reperfusion treatment of acute ST-segment elevation&#xD;
      myocardial infarction.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">January 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 10, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ultrasound and CMR to assess the characteristics of myocardial infarction</measure>
    <time_frame>3 years</time_frame>
    <description>Q-LAB Scale Scale calculation score</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>STEMI</condition>
  <arm_group>
    <arm_group_label>beprostaglandin sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>beprostaglandin sodium</intervention_name>
    <description>beprostaglandin sodium</description>
    <arm_group_label>beprostaglandin sodium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1) Meet the diagnostic criteria for acute ST-segment elevation myocardial infarction:&#xD;
             ①The onset of ischemic chest pain lasts for more than 30 minutes and cannot be&#xD;
             relieved by taking nitroglycerin; ②The ECG has two or more ST-segment elevations in&#xD;
             adjacent leads , Limb leads ≥ 1mm, pectoral leads ≥ 2mm; or newly-appearing left&#xD;
             bundle branch block; ③The increase in serum markers of myocardial necrosis is at least&#xD;
             twice the normal value; (2) Coronary angiography confirmed acute myocardial&#xD;
             infarction; (3) Direct PCI treatment within 12 hours of onset; (4) Complete clinical&#xD;
             and radiographic data.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) Those who do not cooperate in the inspection, have poor compliance, and cannot&#xD;
             guarantee the completion of the test; (2) Persons with consciousness impairment,&#xD;
             obvious intellectual impairment and mental abnormality; (3) With metal foreign bodies,&#xD;
             such as metal prostheses, intraocular metal foreign bodies, intracranial aneurysm&#xD;
             clamps, etc.; (4) Those who suffer from closure phobia; (5) Those who have had a&#xD;
             history of myocardial infarction, PCI treatment, or coronary artery bypass graft; (6)&#xD;
             Factors affecting the changes in the ST segment of the electrocardiogram: complete&#xD;
             left bundle branch block, pre-excitation syndrome, pacemaker electrocardiogram&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Huadong Liu, doctor</last_name>
    <phone>13724397998</phone>
    <email>lhd2578@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shenzhen People' S Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Huadong Liu</last_name>
      <phone>13724397998</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>September 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>September 4, 2021</last_update_submitted>
  <last_update_submitted_qc>September 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Beprostaglandin sodium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

